Drug intelligence / Profile preview

TNK02

Development stage: Preclinical
Lead developer: SynoCare
Modality: Small Molecules

Overview

TNK02 is a preclinical-stage small molecule oncology candidate developed by SynoCare (Synnocare). It is designed using a synthetic lethality strategy, a therapeutic approach that targets specific genetic deficiencies or vulnerabilities in cancer cells to induce cell death while minimizing impact on healthy tissue. The drug is currently being investigated for the treatment of hematologic malignancies, including leukemia and lymphoma, as well as various solid tumors. As of the current pipeline status, the specific molecular target of TNK02 (designated internally as TNK02XX) remains undisclosed by the developer.

Beyond the preview

Go deeper on TNK02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNK02.

Explore the full profile